Eversept Partners’s NewAmsterdam Pharma NAMS Stock Holding History

Eversept Partners’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.34M	Sell	275,471 -10,293	-4%	-$339K	0.48%	51
2026 Q1	$9.15M	Sell	285,764 -135,063	-32%	-$4.4M	0.48%	46
2025 Q4	$14.8M	Sell	420,827 -67,765	-14%	-$2.47M	0.74%	34
2025 Q3	$13.9M	Buy	488,592 +74,162	+18%	+$1.78M	0.96%	27
2025 Q2	$7.51M	Buy	414,430 +133,479	+48%	+$2.43M	0.69%	35
2025 Q1	$5.75M	Buy	280,951 +5,589	+2%	+$124K	0.58%	34
2024 Q4	$7.08M	Sell	275,362 -31,995	-10%	-$680K	0.63%	33
2024 Q3	$5.1M	Sell	307,357 -22,533	-7%	-$390K	0.35%	37
2024 Q2	$6.34M	Sell	329,890 -24,075	-7%	-$483K	0.43%	39
2024 Q1	$8.37M	Sell	353,965 -20,439	-5%	-$415K	0.56%	32
2023 Q4	$4.18M	Sell	374,404 -286,214	-43%	-$2.62M	0.37%	42
2023 Q3	$6.11M	Sell	660,618 -31,751	-5%	-$344K	0.52%	35
2023 Q2	$8.23M	Buy	692,369 +646,513	+1,410%	+$8.58M	0.69%	32
2023 Q1	$608K	Buy	+45,856	New	+$579K	0.04%	61

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Eversept Partners's NAMS Position: Q2 2026 in Review

Eversept Partners reduced its NewAmsterdam Pharma (NAMS) stake by 3.6% in Q2 2026, selling an estimated $339K and leaving 275,471 shares worth $9.34M. The position accounts for 0.48% of the portfolio, ranked #51.

Eversept Partners first reported a position in NAMS in Q1 2023 and has held it in 14 quarters since. The position peaked at $14.8M in Q4 2025. 195 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

Eversept Partners held 275,471 shares of NewAmsterdam Pharma worth $9.34M as of Q2 2026.
Eversept Partners sold 10,293 NewAmsterdam Pharma shares in Q2 2026, an estimated $339K.
NewAmsterdam Pharma made up 0.48% of Eversept Partners's portfolio in Q2 2026, its #51 holding.
Eversept Partners first reported a position in NewAmsterdam Pharma in Q1 2023 and has held it in 14 quarters since.
Eversept Partners's NewAmsterdam Pharma position peaked at $14.8M in Q4 2025.
195 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Eversept Partners's 13F filing for Q2 2026, filed 14 Aug 2026.